Open AccessFlagellate Erythema Secondary to Bleomycin for Non-Seminomatous Testis Tumor
Author(s) -
Felipe de Lacerda Pereira,
Igor Alexandre Protzner Morbeck
Publication year - 2021
Publication title -
brazilian journal of case reports
Language(s) - English
Resource type - Journals
ISSN - 2763-583X
DOI - 10.52600/2763-583x.bjcr.2021.1.3.86-89
Subject(s) - bleomycin , flagellate , erythema , dermatology , chemotherapy , medicine , etoposide , vismodegib , cancer research , biology , basal cell carcinoma , basal cell , botany
The development of flagellate erythema secondary to bleomycin treatment is a rare adverse effect. The prevalence varies between 8 to 22% of patients and it is becoming rarer. Flagellate erythema presents as a scaly erythematous papule. A lower amount of bleomycin hydrolase in regions with reduced production, such as skin and lungs, decreases bleomycin degradation, which allows its accumulation in tissues, triggering an inflammatory process, especially in patients with lower basal enzyme function. We report a clinical case of a severe presentation of flagellate erythema secondary to a patient ongoing bleomycin, etoposide and platinum (BEP) based chemotherapy of non-seminomatous testis cancer.